» Articles » PMID: 38542306

HFE Mutations in Neurodegenerative Disease As a Model of Hormesis

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2024 Mar 28
PMID 38542306
Authors
Affiliations
Soon will be listed here.
Abstract

Common variants in the iron regulatory protein HFE contribute to systematically increased iron levels, yet the effects in the brain are not fully characterized. It is commonly believed that iron dysregulation is a key contributor to neurodegenerative disease due to iron's ability to catalyze reactive oxygen species production. However, whether HFE variants exacerbate or protect against neurodegeneration has been heavily debated. Some claim that mutated HFE exacerbates oxidative stress and neuroinflammation, thus predisposing carriers to neurodegeneration-linked pathologies. However, H63D HFE has also been shown to slow the progression of multiple neurodegenerative diseases and to protect against environmental toxins that cause neurodegeneration. These conflicting results showcase the need to further understand the contribution of HFE variants to neurodegenerative disease heterogeneity. Data from mouse models consistently demonstrate robust neuroprotection against toxins known to increase the risk of neurodegenerative disease. This may represent an adaptive, or hormetic, response to increased iron, which leaves cells better protected against future stressors. This review describes the current research regarding the contribution of HFE variants to neurodegenerative disease prognosis in the context of a hormetic model. To our knowledge, this is the first time that a hormetic model for neurodegenerative disease has been presented.

Citing Articles

Human Leukocyte Antigen and microRNAs as Key Orchestrators of Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review.

Catana C, Marta M, Valeanu M, Dican L, Crisan C Int J Mol Sci. 2024; 25(15).

PMID: 39126112 PMC: 11312697. DOI: 10.3390/ijms25158544.


Investigating hormesis, aging, and neurodegeneration: From bench to clinics.

Calabrese V, Wenzel U, Piccoli T, Jacob U, Nicolosi L, Fazzolari G Open Med (Wars). 2024; 19(1):20240986.

PMID: 38911254 PMC: 11193355. DOI: 10.1515/med-2024-0986.

References
1.
Wang X, Lee S, Simmons Z, Boyer P, Scott K, Liu W . Increased incidence of the Hfe mutation in amyotrophic lateral sclerosis and related cellular consequences. J Neurol Sci. 2004; 227(1):27-33. DOI: 10.1016/j.jns.2004.08.003. View

2.
Lleo A, Blesa R, Angelopoulos C, Villa M, Oliva R, Bufill E . Transferrin C2 allele, haemochromatosis gene mutations, and risk for Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2002; 72(6):820-1. PMC: 1737914. DOI: 10.1136/jnnp.72.6.820-a. View

3.
Chicharro J, Hoyos J, Gomez-Gallego F, Villa J, Bandres F, Celaya P . Mutations in the hereditary haemochromatosis gene HFE in professional endurance athletes. Br J Sports Med. 2004; 38(4):418-21. PMC: 1724889. DOI: 10.1136/bjsm.2002.003921. View

4.
Saini P, Bandres-Ciga S, Alcantud J, Ruz C, Postuma R, Gan-Or Z . Common and rare variants in HFE are not associated with Parkinson's disease in Europeans. Neurobiol Aging. 2021; 107:174-177. PMC: 8595489. DOI: 10.1016/j.neurobiolaging.2021.05.019. View

5.
Feder J, Penny D, Irrinki A, Lee V, Lebron J, Watson N . The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci U S A. 1998; 95(4):1472-7. PMC: 19050. DOI: 10.1073/pnas.95.4.1472. View